Patrick Pétrossians

Patrick Pétrossians

Auto-generated profile, based on publicly available information

Patrick Pétrossians

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2020
Verified
Book Chapter
Open access
PDF file
TDTcharaktchiev Dimitar
Tcharaktchiev Dimitar
EKEvgeniy Krastev
Evgeniy Krastev
PPPetrossians Patrick
Petrossians Patrick
ASAbanos Simeon
Abanos Simeon
KHKyurkchiev Hristo
Kyurkchiev Hristo
KPKovatchev Petko
Kovatchev Petko
This paper proposes an approach and demonstrates its application for cross-border exchange of clinical documents oriented towards the use of archetype concepts and international patient summary standards adopted in the European Union. A novelty in this approach is the management of native XML instances of an archetype concept in the CEN 13606 standard by means of a native XML database and XML technologies. The computer experiments demonstrate that it is suitable for representing relatively small clinical datasets such as those describing rare diseases like the Acromegaly illness, where the semantic context in the relatively small number of symptoms is practicable to tag in terms of SNOMED-CT terminology codes. Additionally, we demonstrate that the semantically enriched information model can facilitate secondary use of clinical data by visualizing the execution of queries based on standard terminologies. Finally, the compatibility of the information model with the IPS standard enables sharing of clinical data among different information models.

30 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
GTGiampaolo Trivellin
Giampaolo Trivellin
VSVíctor Sánchez-Gaya
Víctor Sánchez-Gaya
AGAlexia Grasso
Alexia Grasso
MPMagdalena Pasińska
Magdalena Pasińska
Constantine A. StratakisConstantine A. Stratakis
Constantine A. Stratakis
ADAdrian Daly
Adrian Daly
Background: Structural variants (SVs) that disrupt topologically associating domains (TADs) can cause disease by rewiring enhancer-promoter interactions. Duplications involving GPR101 are known to cause X-linked acrogigantism (X-LAG) by enabling aberrant expression of GPR101 through hijacking of enhancers at VGLL1 . However, not all GPR101 -containing duplications are pathogenic, presenting a diagnostic challenge, especially in the prenatal setting. Methods: We evaluated POSTRE, a tool designed to predict the regulatory impact of SVs, to distinguish pathogenic from benign GPR101 duplications. We analyzed six non-pathogenic duplications, and 27 known X-LAG associated pathogenic duplications. Tissue-specific enhancer maps built using H3K27ac ChIP-seq and ATAC-seq data as well as gene expression data derived from human anterior pituitary samples were integrated into POSTRE to enable predictions in a X-LAG relevant tissue context. Results: POSTRE correctly classified all 33 duplications as benign or pathogenic. In addition, one X-LAG case with mild clinical features (e.g., severe GH hypersecretion in the absence of pituitary tumorigenesis) was found to include only 2/5 VGLL1 enhancers (also predicted to be the weakest enhancers), whereas all 26 typical X-LAG cases had 24 enhancers duplicated. This suggests that milder enhancer hijacking at VGLL1 could explain the different clinical features of X-LAG in this individual. Conclusions: These findings support the utility of POSTRE to support diagnostic pipelines when interpreting SVs affecting chromatin architecture in pituitary disease. By accurately modelling enhancer adoption in a cell type-specific context, POSTRE could help to reduce uncertainty in genetic counselling and offers a rapid alternative to performing chromatin conformation capture experiments.

1 January 2025 in Endocrine Oncology
Verified
Journal Article
Open access
SPSolene Papart
Solene Papart
ADAdrian Daly
Adrian Daly
EBElettra Bianchi
Elettra Bianchi
AJAlexandre Jadoul
Alexandre Jadoul
GRGilles Reuter
Gilles Reuter
ABAlbert Beckers
Albert Beckers
Background: Olfactory neuroblastoma (ONB) is a rare malignant neuroectodermal tumour that usually arises in the nasal cavity, typically presenting with unilateral nasal obstruction and epistaxis. In rare instances, ONB can manifest as a paraneoplastic syndrome of inappropriate antidiuretic hormone (SIADH) secretion, leading to hyponatraemia. Case presentation: We describe a 42-year-old woman with a 4-year history of cyclical, symptomatic hyponatraemia characterised by intermittent episodes of dizziness, severe headaches and marked fatigue, initially without overt nasal or otolaryngological symptoms. Investigations confirmed SIADH, yet repeated imaging (including thoracic CT and FDG PET-CT) failed to identify a source. Eventually, a 68Ga-DOTANOC PET-CT revealed an isolated lesion in the left ethmoid region. Surgical resection via an endoscopic approach confirmed the diagnosis of a Hyams grade 1 ONB. Following complete tumour removal, the patient’s hyponatraemia resolved. Literature review: ONB accounts for <3% of nasal tumours and can present with non-specific symptoms, delaying diagnosis. Most patients have a typical combination of nasal obstruction and epistaxis, but paraneoplastic SIADH is reported in about 2% of cases. Complete surgical excision is the cornerstone of therapy, often accompanied by radiotherapy or chemotherapy for higher-grade lesions. Recent advances suggest that somatostatin receptor imaging and targeted radionuclide therapy might benefit select patients, particularly those with unresectable or recurrent disease. Conclusion: This case highlights the importance of considering ONB in patients with unexplained SIADH, especially when initial investigations are inconclusive. It also underscores the utility of 68Ga-DOTANOC PET-CT in detecting occult neuroendocrine tumours, and reinforces the value of prompt surgical intervention for definitive treatment.

1 January 2026 in Endocrine Oncology
Verified
Journal Article
Open access
DBDaniela Betea
Daniela Betea
PPPatrick Petrossians
Patrick Petrossians
Primary hyperparathyroidism (PHPT), considered a rare disease almost a century ago, has shown a notable increase in incidence over the past five decades, driven largely by improved diagnostic screening and greater clinical awareness. Following the same trend, the incidence of parathyroid carcinoma (PC), a very rare but aggressive malignancy accounting for approximately 1% of PHPT cases, appears to be rising. This increase parallels the overall rise in PHPT detection, suggesting that enhanced surveillance contributes to identifying more PC cases. PC is mostly characterized by severe hypercalcaemia, due to tumoral parathyroid hormone (PTH) over-secretion and a high rate of local recurrence and metastasis, making early diagnosis and surgical treatment crucial. Recent advances in genetics and epigenetics have profoundly expanded our understanding of PC pathogenesis. Germline and somatic mutations in the tumour suppressor gene CDC73 (encoding parafibromin) are implicated in up to 75% of familial and sporadic PC cases. Additional recurrent mutations in genes such as MEN1 and PRUNE2, alterations in cell cycle regulators such as CCND1 and EZH2, and disruptions in signalling pathways including PI3K/AKT/mTOR have been identified. Epigenetic modifications, including microRNA expression changes and promoter hypermethylation, also play a significant role in tumour development and progression. This mini review synthesizes epidemiological trends demonstrating an increasing incidence of PC following the rise of PHPT and highlights pivotal genetic and epigenetic findings contributing to tumourigenesis. Integrating new molecular insights with advances in clinical surveillance offers promise for improved diagnosis, prognostic stratification, and the development of future targeted therapies for parathyroid carcinoma.

16 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ADAdrian Daly
Adrian Daly
KSKalyani Sridharan
Kalyani Sridharan
MJMarie-Lise Jaffrain-Rea
Marie-Lise Jaffrain-Rea
GTGiampaolo Trivellin
Giampaolo Trivellin
FCFrancesca Carbonara
Francesca Carbonara
PPPatrick Pétrossians
Patrick Pétrossians
Introduction: Pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) are common intracranial tumors, clinically affecting 1:1000 individuals and most cases remain genetically unexplained. Emerging research has highlighted the major contribution of germline pathogenic variants to tumorigenesis across many tissue types in young subjects . We investigated whether young-onset (<30 years old) pituitary macroadenomas that were negative for known genetic causes harbor pathogenic or likely pathogenic (P/LP) variants in cancer-risk genes. Methods: We retrospectively analyzed 48 subjects (29 males; 96% GH- or PRL-secreting) with sporadic pituitary macroadenomas that were negative for known germline variants ( AIP, MEN1, CDKN1B ) or duplications ( GPR101 ). Whole-exome sequencing (WES) was performed on germline DNA. Bioinformatics analysis including variant calling (for small variants and CNVs), annotation and variant prioritization were performed, using secondary analysis pipelines for WES data and AION predictor platform for tertiary analysis. Variants in established cancer-risk genes were prioritized. Results: P/LP germline variants in cancer-risk genes were identified in 14.6% of subjects on ClinVar/ACMG criteria. This rose to 31.3% of subject with deleterious variants when additional in silico and AION predictor criteria were used. Genes included: BAP1, BRCA1, BUB1, ELAC2, FLCN, MCPH1, MSR1, MUTYH, PDE11A, POLE, POLG, PMS2, RAD51C, RECQL4, SDHA, SDHD, SEC23B, TMEM127, WRN . Conclusions: Our findings expand the spectrum of genes potentially associated with young-onset pituitary macroadenomas. The identification of a high rate of deleterious germline variants in cancer-risk genes in pituitary adenomas/PitNETs echoes similar findings in young patients across a wide range of tumors. These results may have relevance for genetic counseling and potentially could expand targeted management strategies in young patients with large pituitary tumors.